JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 4, 2004; DOI: 10.1124/jpet.103.063651


0022-3565/04/3093-1174-1182$20.00
JPET 309:1174-1182, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.063651v1
309/3/1174    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fiorucci, S.
Right arrow Articles by Wallace, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fiorucci, S.
Right arrow Articles by Wallace, J. L.

INFLAMMATION AND IMMUNOPHARMACOLOGY

Cooperation between Aspirin-Triggered Lipoxin and Nitric Oxide (NO) Mediates Antiadhesive Properties of 2-(Acetyloxy)benzoic Acid 3-(Nitrooxymethyl)phenyl Ester (NCX-4016) (NO-Aspirin) on Neutrophil-Endothelial Cell Adherence

Stefano Fiorucci, Eleonora Distrutti, Andrea Mencarelli, Giovanni Rizzo, Anna Rita Di Lorenzo, Monia Baldoni, Piero del Soldato, Antonio Morelli, and John L. Wallace

Clinica di Gastroenterologia ed Epatologia, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Perugia, Perugia, Italy (S.F., E.D., A.Me., G.R., A.R.D.L., M.B., A.Mo.); Nicox SA, Sophia Antipolis, France (P.d.S.); and Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada (J.L.W.)

2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) is a nitric oxide (NO)-releasing derivative of aspirin that inhibits cyclooxygenase (COX) activity and releases NO. Acetylation of COX-2 by aspirin activates a transcellular biosynthetic pathway that switches eicosanoid biosynthesis from prostaglandin E2 to 15-epi-lipoxin (LX)A4 or aspirin-triggered lipoxin (ATL). Here, we demonstrate that exposure of neutrophil (PMN)/human umbilical vein endothelial cell (HUVEC) cocultures to aspirin and NCX-4016 triggers ATL formation and inhibits cell-to-cell adhesion induced by endotoxin (LPS) and interleukin (IL)-1{beta} by 70 to 90%. However, although selective and nonselective COX-2 inhibitors (celecoxib, rofecoxib, and naproxen) or N-t-butoxycarbonylmethionine-leucine-phenylalanine (Boc-1), an LXA4 receptor antagonist, reduced the antiadhesive properties of aspirin by {approx}70%, antiadhesive effects of NCX-4016 were only marginally affected ({approx}30%) by COX inhibitors and Boc-1, implying that COX-independent mechanisms mediate the antiadhesive properties of NCX-4016. Indeed, NCX-4016 causes a long-lasting (up to 12 h) release of NO and cGMP accumulation in HUVEC. Scavenging NO with 10 mM hemoglobin, in the presence of celecoxib, reduced the antiadhesive properties of NCX-4016 by {approx}80%. Confirming a role for NO, the NO donor diethylenetriamine-NO also inhibited PMN/HUVEC adhesion by {approx}80%. NCX-4016, but not aspirin, decreased DNA binding of nuclear factor-{kappa}B (NF-{kappa}B) on gel shift analysis and HUVEC's overexpression of CD54 and CD62E induced by LPS/IL-1{beta}. Reduction of binding of the two NF-{kappa}B subunits p50-p50 and p50-p65 was reversed by dithiothreitol, implying S-nitrosylation as mechanism of inhibition. In summary, our results support that ATL and NO are formed at the PMN/HUVEC interface after exposure to NCX-4016 and mediate the antiadhesive properties of this compound.


Received November 29, 2003; accepted February 3, 2004.

Address correspondence to: Dr. Stefano Fiorucci, Clinica di Gastroenterologia ed Endoscopia Digestiva, Policlinico Monteluce, 06100 Perugia, Italy. E-mail: fiorucci{at}unipg.it




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
D. Mitchell, S. J. O'Meara, A. Gaffney, J. K. G. Crean, B. T. Kinsella, and C. Godson
The Lipoxin A4 Receptor Is Coupled to SHP-2 Activation: IMPLICATIONS FOR REGULATION OF RECEPTOR TYROSINE KINASES
J. Biol. Chem., May 25, 2007; 282(21): 15606 - 15618.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. G. Burke, C. L. Wainwright, I. Vojnovic, T. Warner, D. G. Watson, and B. L. Furman
The Effect of NCX4016 [2-Acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl Ester] on the Consequences of Ischemia and Reperfusion in the Streptozotocin Diabetic Rat
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1107 - 1114.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
M. R. Pijak
Rebound Inflammation and the Risk of Ischemic Stroke After Discontinuation of Aspirin Therapy
Arch Neurol, February 1, 2006; 63(2): 300 - 301.
[Full Text] [PDF]


Home page
J. Immunol.Home page
S. Fiorucci, A. Mencarelli, E. Distrutti, M. Baldoni, P. del Soldato, and A. Morelli
Nitric Oxide Regulates Immune Cell Bioenergetic: A Mechanism to Understand Immunomodulatory Functions of Nitric Oxide-Releasing Anti-Inflammatory Drugs
J. Immunol., July 15, 2004; 173(2): 874 - 882.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
M. J. Paul-Clark, T. van Cao, N. Moradi-Bidhendi, D. Cooper, and D. W. Gilroy
15-epi-lipoxin A4-mediated Induction of Nitric Oxide Explains How Aspirin Inhibits Acute Inflammation
J. Exp. Med., July 6, 2004; 200(1): 69 - 78.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.